

## Subject Index

### A

- A-91, A-144, A-145, A-192, and A-195 (amino acid derivatives), activity against various tumor systems, 309
- 1-Acetyl-2-picolinoylhydrazine (NSC-68626), in children with various malignant neoplasms, 341
- Acronycine (NSC-403169), evaluation in the C1300 murine neuroblastoma model, 975
- Actinomycin D (NSC-3053)**  
 combined with procarbazine and vinblastine in the treatment of malignant melanoma, 767  
 combined with vincristine and alternating with adriamycin in the treatment of advanced sarcomas, 1035  
 combined with vincristine and cyclophosphamide with or without radiation therapy in the treatment of childhood rhabdomyosarcoma, 359  
 single dose toxicity of, in dogs, 447  
 tissue disposition of, in the rat, monkey, and dog, 1061
- Acute Leukemia Group B** see Cooperative groups
- ADJ/PC6A tumor** see Tumor systems, mice
- Adriamycin (NSC-123127)**  
 alternating with the combination of vincristine and actinomycin D in the treatment of advanced sarcomas, 1035  
 antitumor activity and cardiotoxicity of, another hypothesis, 258  
 cardiac uptake of, not affected by strophanthin G, 765  
 combined with DTIC in the treatment of advanced, childhood, stage IV neuroblastoma, 1015  
 compared with 5-FU plus cyclophosphamide in the treatment of advanced prostatic cancer, 203  
 compared to 5-FU in the treatment of advanced colorectal cancer, 405  
 compared with 5-FU in the treatment of advanced prostatic cancer, 215  
 contact dermatitis associated with, 677  
 DNA complexes of, 260  
 effect of temperature on drug uptake by leukemic leukocytes in vitro, 985  
 enhancement of the effectiveness of, against early mouse L1210 leukemia with ICRF-159, 689  
 evaluation in the C1300 murine neuroblastoma model, 975  
 new model for studying the effects of, on the growth of the prostate gland in rats, 185  
 phase I study, combined with 5-FU in the treatment of breast cancer and other solid tumors, 1163  
 preliminary pharmacokinetic model for, 819  
 toxicologic screening in rats, 707  
 in the treatment of advanced gastrointestinal cancer, 405  
 in the treatment of alkylator-resistant multiple myeloma, 345  
 treatment of MAC-13 and MAC-15, adenocarcinomas of the colon in mice, 1083  
 in the treatment of metastatic melanoma, 1181  
 used in potential test systems in animals to determine activity against prostatic carcinoma, 175
- Adriamycin-DNA (NSC-169534)**, comparison of different formulations, 260
- Adriamycin, 14-octanoate, hydrochloride (NSC-149584)**, toxicologic screening in rats, 707
- AH13 hepatoma** see Tumor systems, rats
- AH60C hepatoma** see Tumor systems, rats
- AH7974 hepatoma** see Tumor systems, rats
- AKR lymphoma** see Tumor systems, mice
- Aluminum nitrate (NSC-143017)**, toxicity and antitumor activity in experimental rodent tumors, 599
- Amino acid derivatives**, antitumor activity of, against various tumor systems, 309
- L-[ $\alpha$ ,5S]- $\alpha$ -amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (NSC-163501)**, a new amino acid antibiotic with the properties of an antagonist of L-glutamine, as an inhibitor of mammalian and bacterial reactions, 481
- Amygdalin MF (NSC-15780)**  
 antitumor activity of, as a single agent and with  $\beta$ -glucosidase on a spectrum of transplantable rodent tumors, 939  
 experimental studies of the antitumor activity of, alone and combined with  $\beta$ -glucosidase, 951
- Anhydro-ara-5-fluorocytidine (NSC-166641)**, evaluation of sialogic action, 1019
- Announcements**  
 Annual Meeting of the American Association for Cancer Research, Inc, 255  
 67th Annual Meeting of the American Association for Cancer Research, Inc 1205  
 Cancer Therapy Abstracts, 1047  
 Eighth World Congress of Gynecology and Obstetrics, 675, 1047  
 Examination of the American Board of Internal Medicine in the Subspecialty Area of Medical Oncology, 255, 455  
 Fellowships in Medical and Surgical Oncology, 455  
 First EORTC Breast Cancer Working Conference, 676  
 Fourth International Symposium on Senology, 675  
 Hematology/Oncology Fellowship, 1206  
 Immunology Symposium on "Applied Clinical Immunology," 1049  
 Johananoff International Fellowship for Advanced Biomedical Studies, 1049  
 Medical Oncology Course, 676, 883  
 Medical Oncology Fellowship, 1047  
 Memorial Sloan-Kettering Cancer Center Nursing Symposium, 883

Oncology Placement Service, 455, 675, 1205  
 Postdoctoral Fellowships in Drug Development, 1048  
 Postgraduate Course on "Immunology for the Practicing Physician," 884  
 Second Annual Meeting of the Association of Community Cancer Centers, 1048  
 Seventh New Drug Seminar: Nitrosoureas, 1048  
 Sixth New Drug Seminar: Dimethyl Triazeno Imidazole Carboxamide, 456  
 Symposium on Advances in Cancer Treatment Research, 1206  
 Symposium on Breast Cancer, 255  
 Symposium on Modern Concepts in Brain Tumor Therapy: Laboratory and Clinical Investigation, 883, 1205  
 Symposium on "The Non-Hodgkin's Lymphomas," 1205  
 Symposium on Steroid Hormone Action and Cancer, 676  
 Symposium on Tumor and Clinical Tumor Immunity, 456  
 Training Program in Medical Oncology, 675, 1047  
 Wisconsin Clinical Cancer Center Tenth National Conference, 455  
 Workshop on Antimetabolites and the Central Nervous System, 1048

**Antiviral chemotherapy**, as an adjunct to cancer chemotherapy, 261

#### Assay techniques

assay for citrovorum factor in the presence of methotrexate, 935  
 chemical assay to determine concentrations of inosine dialdehyde in biologic fluids, 685  
 microbiologic assay for cytosine arabinoside, using a mutant of *Streptococcus faecium* var. *durans* resistant to methotrexate and 6-MP, 515  
 new in vitro method for assaying colony-forming cells of Lewis lung carcinoma and B16 melanoma, comparison of effects of three nitrosoureas, 929  
 a useful biologic assay for tetrahydrouridine, a potent inhibitor of cytosine arabinoside deamination, 717

#### 5-Azacytidine (NSC-102816)

combined with methyl-GAG in previously treated adults with acute nonlymphocytic leukemia, 1043  
 enhancement by tetrahydrouridine of the oral activity of, in L1210 leukemic mice, 459  
 phase I study of, using a 24-hr continuous infusion for 5 days in the treatment of various cancers, 1123

## B

#### *Bacillus Calmette-Guérin*

immunotherapy of prostatic cancer with, 157  
 for prostatic cancer in man, 251

BCG see *Bacillus Calmette-Guérin*

#### BCNU (NSC-409962)

analysis of the effects of, on cell cycle kinetics, 847  
 combined with cyclophosphamide in the remission maintenance of adult acute nonlymphocytic leukemia, 537  
 compared to methyl-CCNU and CCNU with regard to sensitivity of colony-forming cells of hemopoietic tissue, Lewis lung carcinoma, and B16 melanoma, 929  
 effect of, alone or combined with levamisole, on DNA syn-

thesis by lymphocytes from immunosuppressed C57BL mice, 531

evaluation in the C1300 murine neuroblastoma model, 975

treatment of MAC-13 and MAC-15, adenocarcinomas of the colon in mice, 1083

#### BIC (NSC-82196)

phase II clinical trial of, in primary and secondary brain tumors, 327

plus CCNU in patients with various disseminated solid tumors, 769.

in the treatment of childhood malignancy, 371

#### Bleomycin (NSC-125066)

alone or in combination with CCNU in the treatment of metastatic testicular cancer, 429

combined with CCNU in the treatment of MOPP-resistant Hodgkin's disease, 1147

combined with vincristine and methotrexate plus radiation therapy in the treatment of non-oat-cell bronchogenic cancer, 377

continuous iv therapy combined with vinblastine in stage III testicular neoplasia, 563

evaluation in the C1300 murine neuroblastoma model, 975

reversible penile calcifications associated with pulmonary toxicity induced by, 1039

in the treatment of metastatic liver cancer, 433

used in potential test systems in animals to determine activity against prostatic cancer, 175

B16 melanoma see Tumor systems, mice

Brain cancer see Cancer, brain

Brain tumor models see Tumor systems

Breast cancer see Cancer, breast

Bretylium tosylate (NSC-62164), unorthodox therapy for murine neuroblastoma with, 571

2-Bromo-a-ergocryptine (NSC-169774), clinical trial in the treatment of human prostatic cancer, 209

Bronchogenic carcinoma see Cancer, lung

Burkitt's lymphoma see Lymphoma, Burkitt's

Butyric acid (NSC-8415), unorthodox therapy for murine neuroblastoma with, 571

## C

Calusterone (NSC-88536), antitumor activity of, in advanced breast cancer, 890

#### Cancer (nonhematologic)

##### brain

phase II study of methyl-CCNU, 1022

primary and secondary, phase II clinical trial of BIC in, 327

##### breast

advanced, antitumor activity of calusterone in the treatment of, 890

advanced, cyclophosphamide combined with cytosine arabinoside and methotrexate in the treatment of, 1091

cis-dichlorodiammineplatinum(II) alone and in combination in the treatment of, 647

- combination chemotherapy for, 893
- combinations of cyclophosphamide, vincristine, and 5-FU in the treatment of, 425
- phase I study of 5-FU plus adriamycin in the treatment of, 1163
- VP-16-213 given orally in the treatment of, 1027
- bronchogenic, 5-FU compared to cyclophosphamide in the treatment of, 1025
- colon
  - comparison of mitomycin C and 5-FU using hepatic arterial infusion for liver metastases resulting from, 401
  - vincristine plus 5-FU in the treatment of, 425
- colorectal
  - advanced, adriamycin in the treatment of, 405
  - advanced, phase II study of chromomycin A<sub>3</sub> in, 577
  - advanced, phase II study of cytembena in, 581
  - advanced, phase II study of ICRF-159 in, 761
- epithelial, phase I evaluation of cyclocytidine in the treatment of, 389
- gastrointestinal
  - advanced, methyl-CCNU alone or in combination with cyclophosphamide in the treatment of, 1161
  - cis-dichlorodiammineplatinum(II) alone and in combination in the treatment of, 647
  - 5-day iv infusion with 5-FU after weekly 5-FU failure, 1177
  - phase II study of methyl-CCNU, 1021
  - VP-16-213 given orally in the treatment of, 1027
- genitourinary
  - cis-dichlorodiammineplatinum(II) alone and in combination in the treatment of, 647
  - VP-16-213 given orally in the treatment of, 1027
- head and neck
  - cis-dichlorodiammineplatinum(II) in the treatment of, 621
  - phase II study of methyl-CCNU, 1021
- kidney, metastatic, vincristine combined with hydroxyurea in the treatment of, 1159
- large bowel, metastatic, phase II trials with procarbazine, streptozotocin, 6-thioguanine, or CCNU in patients with, 333
- lip, residual or relapsing, 5-FU applied in a mouthwash in the topical treatment of, 1052
- liver, metastatic, clinical trial of bleomycin in the treatment of, 433
- lung
  - advanced, cyclophosphamide combined with cytosine arabinoside and methotrexate in the treatment of, 1091
  - chemotherapeutic response and iv hyperalimentation in, 437
  - cyclophosphamide in the treatment of, 411
  - epidermoid, phase I-II studies of emetine in the treatment of, 1171
  - non-oat-cell, bleomycin, vincristine, and methotrexate plus radiation therapy in the treatment of, 377
  - phase I study of guanazole in, 1117
  - phase I study of thalicipine in, 1001
  - phase II study of methyl-CCNU in, 1021
  - small cell, methyl-CCNU, cyclophosphamide, and vincristine in the treatment of, in a 3-week schedule, 1127
  - trials with NSC-140117, 367
  - VP-16-213 given orally in the treatment of, 1027
  - VP-16-213 in the treatment of, 737
- ovarian
  - cis-dichlorodiammineplatinum(II) in the treatment of, 621
  - combinations of cyclophosphamide, vincristine, and 5-FU in the treatment of, 425
  - phase II study of methyl-CCNU, 1021
  - recurrent or progressive, high-dose cyclophosphamide in the treatment of, 1157
- pancreas
  - combinations of cyclophosphamide, vincristine, and 5-FU in the treatment of, 425
  - 5-FU in the treatment of: comparison of oral and iv routes, 1031
- prostate
  - advanced, comparison of adriamycin and the combination of 5-FU and cyclophosphamide in the treatment of, 203
  - advanced, comparison of adriamycin and 5-FU in the treatment of, 215
  - advanced, comparison of 5-FU and cyclophosphamide in the treatment of, 195
  - advanced, stage D, oral estramustine phosphate in the treatment of, 219
  - characterization of, among blacks, 3
  - clinical trial of 2-bromo- $\alpha$ -ergocryptine in the treatment of, 209
  - collection of postmortem prostate tissue under sterile conditions, 91
  - cultivation of epithelial cells from the prostate to develop an immune cytotoxicity assay for, 147
  - detection of, 139
  - detection and diagnosis of: general discussion, 151
  - disaggregation of prostates and purification of epithelial cells from normal and cancerous prostates using sedimentation in an isokinetic density gradient of Ficoll in tissue culture medium, 143
  - etiology and prevention of, 65, 73, 89
  - extended-field radiation therapy for, 165
  - far-advanced, clinical results with estramustine phosphate: comparison of iv and oral preparations, 229
  - grading of, 111
  - immunotherapy of, with BCG, 157
  - investigation of specific antigens in, 105
  - monolayer cultures of human prostatic cells, 59
  - neoplastic effect of 3-methylcholanthrene on human prostate in organ culture, 67
  - potential screening agents for, 119
  - potential test systems in animals to predict for activity against, 175
  - a review of clinical trials by the Veterans' Administration Cooperative Urological Research Group, 225
  - search for virogene in, 39
  - stage D, 5-FU versus CCNU and 5-FU plus diethylstilbestrol versus diethylstilbestrol alone in the treatment of, 243
  - treatment of: general discussion, 251
  - tumor antigen and acid phosphatase isoenzyme in, 97

- virologic and immunologic studies of, 17
- virology of, 33
- reticulum cell, phase II study of methyl-CCNU, 1021
- squamous cell, *cis*-dichlorodiammineplatinum(II) alone and in combination in the treatment of, 647
- stomach
  - advanced, adriamycin in the treatment of, 405
  - combinations of cyclophosphamide, vincristine, and 5-FU in the treatment of, 425
- testicular
  - cis*-dichlorodiammineplatinum(II) in the treatment of, 621
  - metastatic, bleomycin alone or combined with CCNU in the treatment of, 429
  - stage III, continuous iv bleomycin therapy combined with vinblastine in, 563
- Carcinogenesis**, cancer chemotherapeutic agents and, 915
- Carcinoma** *see* Cancer, type of
- Cardiotoxicity** *see* Toxic reactions: man
- CCNU (NSC-79037)**
  - combined with bleomycin in the treatment of metastatic testicular carcinoma, 429
  - combined with bleomycin in the treatment of MOPP-resistant Hodgkin's disease, 1147
  - compared to methyl-CCNU and BCNU with regard to sensitivity of colony-forming cells of hemopoietic tissue, Lewis lung carcinoma, and B16 melanoma, 929
  - new model for studying the effects of, in the growth of the prostate gland in rats, 185
  - phase II trials with, in patients with metastatic cancer of the large bowel, 333
  - plus BIC in patients with various disseminated solid tumors, 769
  - treatment of MAC-13 and MAC-15, adenocarcinomas of the colon in mice, 1083
  - used for the prevention of CNS involvement in Burkitt's lymphoma, 1155
  - used in potential test systems in animals to determine activity against prostatic carcinoma, 175
  - versus 5-FU in the treatment of stage D prostatic adenocarcinoma, 243
- CEA (carcinoembryonic antigen)**, in plasma and prostatic fluid from man, dog, and baboon, 97
- Cell culture studies**
  - action of *cis*-dichlorodiammineplatinum(II), 665
  - activity of concanavalin A on KHT fibrosarcoma and AKR lymphoma cells, 319
  - L-[ $\alpha$ ,S,5S]- $\alpha$ -amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid in the treatment of L1210 cells, 481
  - attempts to establish human prostatic tumors in culture, 47
  - disaggregation of prostates and purification of epithelial cells from normal and cancerous prostates using sedimentation in an isokinetic density gradient of Ficoll, 143
  - effect of dianhydrogalactitol on survival and phase sensitivity of the cell cycle of HeLa cells, 493
  - investigation of specific antigens in human prostatic cancer, 105
  - microbiologic assay for cytosine arabinoside, 515
  - monolayer cultures of human prostatic cells, 59
  - preliminary observations on temperature-enhanced drug uptake by leukemic leukocytes, 985
  - properties of prostatic tissue transformed by SV40, 51
  - 6C3HED/OG lymphosarcoma *see* Tumor systems, mice
- Children's Cancer Study Group** *see* Cooperative groups
- Chlorambucil (NSC-3088)**, treatment of MAC-13 and MAC-15, adenocarcinomas of the colon in mice, 1083
- Chloroquine (NSC-187208)**, combined with cyclophosphamide and prednisone in the treatment of multiple myeloma resistant to melphalan, 557
- Chromomycin A<sub>3</sub> (NSC-58514)**, phase II study of, in advanced colorectal cancer, 577
- Cis*-dichlorobiscyclopentylamineplatinum(II)**
  - antitumor activity and tissue distribution of, in animals, 629
  - chemistry of, 589
  - preliminary clinical studies with, 647
- Cis*-dichlorodiammineplatinum(II) (NSC-119875)**
  - action of, at the cellular level, 665
  - alone or combined with various other agents in the treatment of murine leukemia L1210, 629
  - antitumor activity of, in various animal tumors, 589
  - biologic and chemical effects of, on DNA, 643
  - combined with cyclophosphamide in the treatment of human malignancies, 995
  - compared to other platinum compounds, activity against experimental animal tumors, 287
  - hearing loss and other toxic effects in rhesus monkeys treated with, 467
  - tissue analysis, toxicity, and antitumor activity of in nonleukemic patients, 647
  - in the treatment of lymphomas and ovarian, head and neck, and testicular cancers, 621
- Citrovorum factor (NSC-3590)**
  - absorption of, from a "mouthwash," in man, 575
  - assay for, in the presence of methotrexate, 935
- Colchicine (NSC-757)**, activated specifically by PAP, as a potential cytotoxic agent, 233
- Colon cancer** *see* Cancer, colon; Cancer, large bowel
- Colorectal cancer** *see* Cancer, colorectal (*also* other individual sites)
- Combination chemotherapy** (*see also* individual agents)
  - ineffective single agents used in, 259
  - synergistic interaction of anticancer agents: a cellular perspective, 895
  - using agents with limited effectiveness, 457
- Commentaries**
  - Antiviral Chemotherapy as an Indicated Adjunct to Cancer Chemotherapy, 261
  - Cancer Chemotherapeutic Agents and Carcinogenesis, 915
  - Current Status of Clinical Immunotherapy, 901
  - Laminar Air Flow Room Reverse Isolation and Microbial Suppression to Prevent Infection in Patients With Cancer, 1055
  - The Role of Structure-Activity Studies in the Design of Antitumor Agents, 679
  - Synergistic Interaction of Anticancer Agents: A Cellular Perspective, 895
- Concanavalin A (NSC-143504)**, action on experimental tumor cells and possible use in cancer chemotherapy, 319



### Cooperative groups

- Acute Leukemia Group B**, multiple myeloma resistant to melphalan treated with cyclophosphamide and prednisone with or without chloroquine, 557
- Children's Cancer Study Group**  
adriamycin combined with DTIC in the treatment of advanced, childhood, stage IV neuroblastoma, 1015  
dibromodulcitol compared with cyclophosphamide as remission maintenance therapy in previously treated children with acute lymphocytic or acute undifferentiated leukemia: possible effectiveness in reducing the incidence of central nervous system leukemia, 989  
standard-dose cyclophosphamide vs high-dose cyclophosphamide vs cyclophosphamide with cytosine arabinoside in the maintenance treatment of childhood acute lymphocytic leukemia, 1097
- Eastern Oncology Group**, phase II trials with streptozotocin, procarbazine, 6-thioguanine, or CCNU in patients with metastatic cancer of the large bowel, 333
- European Organization for Research on Treatment of Cancer (EORTC) Genito-Urinary Tract Cancer Group B**, clinical trial of 2-bromo- $\alpha$ -ergocryptine in the treatment of human prostatic cancer, 209
- Southwest Oncology Group**  
BIC in the treatment of childhood malignancy, 371  
clinical trials with 1-acetyl-2-picolinoylethylhydrazine in children with various malignant neoplasms, 341  
methotrexate alone or combined with daunorubicin in the remission-maintenance treatment of acute lymphocytic leukemia, 395  
phase I clinical study of guanazole in the treatment of various tumors, 1117  
phase I study of adriamycin combined with 5-FU in the treatment of breast cancer and other solid tumors, 1163  
various combinations of cyclophosphamide, vincristine, and 5-FU in the treatment of adenocarcinoma, 425
- Veteran's Administration Urological Research Group**, studies of prostatic cancer, 225
- Western Cancer Study Group**  
determination of 5-FU plasma levels in rats and man by isotope dilution-mass fragmentography, 279  
5-FU in the treatment of pancreatic cancer: comparison of oral and iv routes, 1031
- COP (cyclophosphamide, vincristine [Oncovin], and prednisone)** see Individual drugs
- Corynebacterium parvum**, phase I study in patients with various solid tumors, 1139
- Cyclocytidine (NSC-145668)**  
distribution of, compared with cytosine arabinoside in mice, 501  
evaluation of sialogogic action of, 1019  
phase I evaluation of, in the treatment of acute leukemia and solid tumors, 389
- Cyclophosphamide (NSC-26271)**  
combined with BCNU in the remission maintenance of adult acute nonlymphocytic leukemia, 537  
combined with *cis*-dichlorodiammineplatinum(II) in the treatment of human malignancies, 995  
combined with cytosine arabinoside and methotrexate in the treatment of advanced breast and lung cancer, 1091  
combined with 5-FU with or without vincristine in the treatment of various adenocarcinomas, 425  
combined with methyl-CCNU in a comparative study with DTIC plus vincristine in patients with disseminated malignant melanoma, 451  
combined with methyl-CCNU in the treatment of advanced gastrointestinal cancer, 1161  
combined with methyl-CCNU and vincristine in the treatment of small cell cancer of the lung in a 3-week schedule, 1127  
combined with prednisone with or without chloroquine in the treatment of multiple myeloma resistant to melphalan, 557  
combined with vincristine and actinomycin D with or without radiation therapy in the treatment of childhood rhabdomyosarcoma, 359  
compared with dibromodulcitol as remission maintenance therapy in previously treated children with acute lymphocytic or acute undifferentiated leukemia: possible effectiveness in reducing the incidence of central nervous system leukemia, 989  
compared with 5-FU in patients with advanced prostatic cancer, 195  
compared to 5-FU in the treatment of bronchogenic cancer, 1025  
evaluation in the C1300 murine neuroblastoma model, 975  
given alone or combined with vincristine and prednisone in the treatment (COP) of diffuse non-Hodgkin's lymphoma, 421  
high-dose, in the treatment of recurrent or progressive ovarian adenocarcinoma, 1157  
inhibition of antilymphoma allograft response in normal and lethally irradiated mice by, 967  
immediate cerebral symptoms during rapid iv administration of, 441  
new model for studying the effects of, on the growth of the prostate gland in rats, 185  
plus 5-FU, compared with adriamycin in the treatment of advanced prostatic cancer, 203  
standard dose vs high dose vs cyclophosphamide plus cytosine arabinoside in the maintenance treatment of childhood acute lymphocytic leukemia, 1097  
treatment of MAC-13 and MAC-15, adenocarcinomas of the colon in mice, 1083  
in the treatment of nonlymphoid solid tumors, 411  
used in potential test systems in animals to determine activity against prostatic cancer, 175
- Cyproterone acetate (NSC-81430)**, new model for studying the effects of, in the growth of the prostate gland in rats, 185
- Cytembena (NSC-104801)**  
nephrotoxic effects of, in dogs and monkeys, 1071  
phase II study of, in advanced colorectal cancer, 581
- Cytosine arabinoside (NSC-63878)**  
analysis of the effects of, on cell cycle kinetics, 847  
combined with cyclophosphamide and compared to high-dose cyclophosphamide or standard-dose cyclophosphamide in the maintenance treatment of childhood acute lymphocytic leukemia, 1097  
combined with cyclophosphamide and methotrexate in

the treatment of advanced breast and lung cancer, 1091  
combined with daunorubicin, 6-thioguanine, prednisone,  
and vincristine in the treatment of adults with acute  
nonlymphocytic leukemia, 1131  
combined with daunorubicin, vincristine, and prednisone  
in the treatment of advanced adult acute leukemia, 757  
disposition of, and its metabolites: a pharmacokinetic  
simulation, 861  
distribution of, compared with cycloctidine in mice, 501  
inhibition of deamination of, by rhodium(II) acetate, 661  
inhibition of deamination of, by tetrahydrouridine, 717  
microbiologic assay for, using a mutant of *Streptococcus*  
*faecium* var. *durans* resistant to methotrexate and 6-  
MP, 515

## D

- Daunomycin, N-(butylcarbonyl)- (NSC-143496)**, toxicologic screening in rats, 707  
**Daunomycin-semicarbazone (NSC-143114)**, toxicologic screening in rats, 707  
**Daunorubicin (NSC-82151)**  
antitumor activity and cardiotoxicity of, another hypothesis, 258  
combined with cytosine arabinoside, 6-thioguanine, prednisone, and vincristine in the treatment of adults with acute nonlymphocytic leukemia, 1131  
combined with methotrexate in the remission-maintenance treatment of acute lymphocytic leukemia, 395  
combined with vincristine, cytosine arabinoside, and prednisone in the treatment of advanced adult acute leukemia, 757  
contact dermatitis associated with, 677  
DNA complexes of, 260  
enhancement of the effectiveness of, combined with adriamycin against early mouse L1210 leukemia with ICRF-159, 689  
toxicologic screening in rats, 707  
**Daunorubicin-DNA (NSC-169533)**, comparison of different formulations of, 260  
**DES** see Diethylstilbestrol  
**Dianhydrogalactitol (NSC-132313)**, survival and phase sensitivity of HeLa cells treated with, 493  
**Dibromodulcitol (NSC-104800)**, compared with cyclophosphamide as remission maintenance therapy in previously treated children with acute lymphocytic or acute undifferentiated leukemia: possible effectiveness in reducing the incidence of central nervous system leukemia, 989  
**Diethylstilbestrol (NSC-3070)**  
plus 5-FU or alone in the treatment of stage D prostate adenocarcinoma, 243  
in the treatment of prostatic carcinoma, 225  
**Diglycolaldehyde** see Inosine dialdehyde  
**DNA**, biologic and chemical effects of *cis*-dichlorodiammineplatinum(II) on, 643  
**DTIC (NSC-45388)**  
combined with adriamycin in the treatment of advanced, childhood, stage IV neuroblastoma, 1015  
combined with vincristine in a comparative study with

cyclophosphamide plus methyl-CCNU in patients with disseminated malignant melanoma, 451  
evaluation in the C1300 murine neuroblastoma model, 975  
new model for studying the effects of, in the growth of the prostate gland in rats, 185  
stochastic compartmental modeling of the disposition of, 843  
in the treatment of solid tumors in children, 351  
used in potential test systems in animals to determine activity against prostatic carcinoma, 175

## E

- Eastern Cooperative Oncology Group** see Cooperative groups  
**Ehrlich carcinoma** see Tumor systems, mice  
**Emetine (NSC-33669)**, phase I-II studies in the treatment of epidermoid bronchogenic cancer, 1171  
**EORTC** see Cooperative groups  
**Epipodophyllotoxins** see VM-26 and VP-16-213  
**Epithelial carcinoma** see Cancer, epithelial  
**Estradiol (NSC-9895)**, new model for studying the effects of, in the growth of the prostate gland in rats, 185  
**Estramustine phosphate (NSC-89199)**  
clinical results with, in far-advanced prostatic carcinoma: comparison of iv and oral preparations, 229  
new model for studying the effects of, in the growth of the prostate gland in rats, 185  
oral, in the treatment of advanced (stage D) prostatic carcinoma, 219  
**European Organization for Research on Treatment of Cancer (EORTC) Genito-Urinary Tract Cancer Cooperative Group B** see Cooperative groups

## F

- 5-Fluorouracil (NSC-19893, 5-FU)**  
applied in a mouthwash in the treatment of residual or relapsing cancer of the lip or buccal mucosa, 1052  
cardiotoxicity of, in man, 1051  
combined with cyclophosphamide and/or vincristine in the treatment of various adenocarcinomas, 425  
combined with methotrexate and prednisolone in the treatment of hepatoma, 1167  
compared to adriamycin in the treatment of advanced colorectal cancer, 405  
compared with adriamycin in the treatment of advanced prostatic cancer, 215  
compared with cyclophosphamide in patients with advanced prostatic cancer, 195  
compared to cyclophosphamide in the treatment of bronchogenic cancer, 1025  
compared to mitomycin C using hepatic arterial infusion for liver metastases from colon cancer, 401  
comparison of oral and iv routes in the treatment of pancreatic cancer, 1031  
5-day iv infusion after failure on weekly therapy in gastroenteric cancer, 1177

determination of plasma levels in rats and man by isotope dilution-mass fragmentography, 279  
 evaluation in the C1300 murine neuroblastoma model, 975  
 new model for studying the effects of, on the growth of the prostate gland in rats, 185  
 phase I study, combined with adriamycin in the treatment of breast cancer and other solid tumors, 1163  
 plus cyclophosphamide, compared with adriamycin in the treatment of advanced prostatic cancer, 203  
 plus diethylstilbestrol vs diethylstilbestrol alone in the treatment of stage D prostatic adenocarcinoma, 243  
 for prostatic cancer in man, 251  
 treatment of MAC-13 and MAC-15, adenocarcinomas of the colon in mice, 1083  
 used in potential test systems in animals to determine activity against prostatic cancer, 175  
 versus CCNU in the treatment of stage D prostatic adenocarcinoma, 243

## G

**Gallium nitrate** (NSC-15200), toxicity and antitumor activity in experimental rodent tumors, 599  
**Gastrointestinal cancer** *see* Cancer, gastrointestinal (*also* other individual sites)  
**Genitourinary cancer** *see* Cancer, genitourinary (*also* other individual sites)  
**Glioma 26** *see* Tumor systems, mice  
 **$\beta$ -Glucosidase** (NSC-128056)  
 antitumor activity of amygdalin MF as a single agent and combined with, on a spectrum of transplantable rodent tumors, 939  
 combined with amygdalin MF, experimental studies of the antitumor activity of, 951  
**Gompertz growth curves**, estimation of tumor cell kill from, 267  
**Guanazole** (NSC-1895)  
 evaluation in the C1300 murine neuroblastoma model, 975  
 phase I study of, in the treatment of various tumors, 1117  
**Guest editorial**, Combination Chemotherapy for Breast Cancer, 893

## H

**Head and neck cancer** *see* Cancer, head and neck  
**HeLa cells** *see* Cell culture studies  
**Hepatic arterial infusion**, for liver metastases from colon cancer: comparison of 5-FU and mitomycin C, 401  
**Hepatoma**, combination of 5-FU, methotrexate, and prednisolone in the treatment of, 1167  
**Hexamethylmelamine** (NSC-13875), used in potential test systems in animals to determine activity against prostatic cancer, 175  
**L-lyxo-Hexopyranoside**, 3- $\beta$ -acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1 $\alpha$ -naphthacenyl-3-acetamido-2,3,6-trideoxy-,  $\alpha$ -, compd. with isopropyl alcohol (1:1) (NSC-118714), toxicologic screening in rats, 707

**Hodgkin's disease**, MOPP-resistant, bleomycin combined with CCNU in the treatment of, 1147  
**Hydrazine sulfate** (NSC-150014), in the treatment of various cancers, 1151  
**6-Hydroxydopamine** (NSC-233898), unorthodox therapy for murine neuroblastoma with, 571  
**Hydroxyurea** (NSC-32065)  
 combined with vincristine in the treatment of metastatic renal cancer, 1159  
 new model for studying the effects of, in the growth of the prostate gland in rats, 185  
**Hyperalimentation**, iv, chemotherapeutic response in patients given, 437  
**Hyperthermia**  
 as an adjuvant in the treatment of osteogenic sarcoma, 257  
 preliminary observations on temperature-enhanced drug uptake by leukemic leukocytes *in vitro*, 985

## I

**ICRF-159** (NSC-129943)  
 evaluation in the C1300 murine neuroblastoma model, 975  
 phase II study of, in advanced colorectal cancer, 761  
 used to enhance the effectiveness of daunorubicin or adriamycin against early mouse L1210 leukemia, 689  
**Imidazole carboxamides** (*see also* DTIC and BIC), relationship of lipophilicity to activity against intracerebral murine Glioma 26, 327  
**Immunotherapy** (*see also* Bacillus Calmette-Guerin)  
 current status of, 901  
 inhibition of antilymphoma allograft response in normal and lethally irradiated mice by cyclophosphamide and isophosphamide, 967  
 prostatic cancer treated with bacillus Calmette-Guerin, 157  
**Indium nitrate**, toxicity and antitumor activity in experimental rodent tumors, 599  
**Inosine dialdehyde** (NSC-118994)  
 chemical assay to determine concentrations of, in biological fluids, 685  
 phase I study of, 1007  
 used in potential test systems in animals to determine activity against prostatic cancer, 175  
**Isophosphamide** (NSC-109724)  
 evaluation in the C1300 murine neuroblastoma model, 975  
 human pharmacokinetic model for, 877  
 inhibition of antilymphoma allograft response in normal and lethally irradiated mice by, 967  
 phase I study of, 751  
 used in potential test systems in animals to determine activity against prostatic cancer, 175

## K

**KHT fibrosarcoma** *see* Tumor systems, mice  
**Kidney cancer** *see* Cancer, kidney

## L

**Laetrile** *see* Amygdalin MF

**LAF-17 lymphoma** *see* Tumor systems, mice

**Laminar air flow rooms**, use of, and microbial suppression to prevent infection in patients with cancer, 1055

**Lankacidin C** (NSC-145118), antitumor and immunosuppressive activity against experimental tumors in mice, 919

**Lankacidin-group antibiotics**, antitumor and immunosuppressive activities of, structure-activity relationships, 919

**Large bowel cancer** *see* Cancer, large bowel

### Letters

Another Hypothesis Concerning the Antitumor Activity and Cardiotoxicity of Daunorubicin (NSC-82151) and Adriamycin (NSC-123127), 258

Antitumor Activity of Calusterone (NSC-88536) in Advanced Breast Cancer, 890

Cardiotoxicity of 5-FU (NSC-19893), 1051

Combination Chemotherapy Using Agents With Limited Effectiveness, 457

Contact Dermatitis Associated With Adriamycin (NSC-123127) and Daunorubicin (NSC-82151), 677

DNA Complexes of Daunorubicin (NSC-82151) and Adriamycin (NSC-123127), 260

Further Discussion of Ineffective Single Agents in Combination Chemotherapy, 259

Hyperthermia as an Adjuvant in the Treatment of Osteogenic Sarcoma, 257

Intraoral Topical Application of 5-FU (NSC-19893) as a "Mouthwash" in the Treatment of Residual or Relapsing Cancer of the Lip or Buccal Mucosa, 1052

Metastatic Renal Adenocarcinoma Produced by Streptozotocin (NSC-85998), 891

Myocardial Infarction in a 27-Year-Old Woman: Possible Complication of Treatment With VP-16-213 (NSC-141540), Mediastinal Irradiation, or Both, 887

Should the Diverse Biologic Activity of Effective Antitumor Agents be Considered a Hindrance to Their Clinical Use?, 888

**Leucovorin** *see* Citrovorum factor

### Leukemia

#### acute

in adults, advanced, daunorubicin, vincristine, cytosine arabinoside, and prednisone combination therapy for, 757

#### lymphocytic

childhood, BIC in the treatment of, 371

childhood, methotrexate alone or combined with daunorubicin in the remission-maintenance treatment of, 395

childhood, preliminary observations of VM-26 and VP-16-213 in, 743

childhood, previously treated, dibromodulcitol compared with cyclophosphamide in the maintenance treatment of: possible effectiveness in reducing the incidence of central nervous system leukemia, 989

childhood, standard-dose cyclophosphamide vs high-dose cyclophosphamide vs cyclophosphamide combined with cytosine arabinoside in the maintenance treatment of, 1097

phase I evaluation of cycloctidine in the treatment of, 389

streptozotocin in the treatment of, 443

monocytic, childhood, vinblastine with or without prednisone in the treatment of, 385

myelogenous, phase I evaluation of cycloctidine in the treatment of, 389

#### nonlymphocytic

in adults, 5-azacytidine combined with methyl-GAG in the treatment of, 1043

in adults, BCNU combined with cyclophosphamide in the remission maintenance of, 537

in adults, daunorubicin combined with cytosine arabinoside, 6-thioguanine, prednisone, and vincristine in the treatment of, 1131

childhood, preliminary observations of VM-26 and VP-16-213 in, 743

undifferentiated, childhood, previously treated, dibromodulcitol compared with cyclophosphamide in the maintenance treatment of: possible effectiveness in reducing the incidence of central nervous system leukemia, 989

central nervous system, dibromodulcitol compared with cyclophosphamide as remission maintenance therapy in previously treated children with acute lymphocytic or acute undifferentiated leukemia: possible effectiveness in reducing the incidence of, 989

chronic lymphocytic, phase I-II studies of mitoclomine in the treatment of, 1173

### Levamisole (NSC-177023)

effects of, alone or combined with BCNU, on DNA synthesis by lymphocytes from immunosuppressed C57BL mice, 531

effects of, in experimental tumor systems, 697

**Lewis lung carcinoma** *see* Tumor systems, mice

**Lip cancer** *see* Cancer, lip

**Liver cancer** *see* Cancer, liver

**Liver metastasis**, from colon cancer, comparison of mitomycin C and 5-FU using hepatic arterial infusion, 401

**L1210 leukemia** *see* Tumor systems, mice

**L5MF lymphoma** *see* Tumor systems, mice

**Lung cancer** *see* Cancer, lung

### Lymphoma

Burkitt's, CCNU used for the prevention of central nervous system involvement in, 1155

Burkitt's, potential biologic markers in, 721

cis-dichlorodiammineplatinum(II) in the treatment of, 621

histiocytic and poorly differentiated, streptozotocin in the treatment of, 443

prognosis of diffuse non-Hodgkin's, treated with COP or cyclophosphamide alone, 421

## M

**MAC-13 adenocarcinoma** *see* Tumor systems, mice

**MAC-15 adenocarcinoma** *see* Tumor systems, mice



**Madison 109 lung tumor** *see* Tumor systems, mice  
**Mass fragmentography**, isotope dilution, determination of 5-FU plasma levels in rats and man by, 279  
**MCAM-7 fibrosarcoma** *see* Tumor systems, mice  
**MCDV-12 leukemia** *see* Tumor systems, mice

# **Melanoma**

disseminated malignant, comparative study of methyl-CCNU with cyclophosphamide and DTIC with vincristine in patients with, 451  
 malignant, treatment of, with vinblastine, procarbazine, and actinomycin D, 767  
 metastatic, adriamycin in the treatment of, 1181  
 phase I study of guanazole in, 1117

# **Melphalan (NSC-8806)**

multiple myeloma resistant to, treated with cyclophosphamide and prednisone, with or without chloroquine, 557  
 treatment of MAC-13 and MAC-15, adenocarcinomas of the colon in mice, 1083

# **6-Mercaptopurine (NSC-755, 6-MP)**, development of a microbiologic assay capable of detecting cytosine arabinoside in body fluids in the presence of, 515

**Methanesulfonates** *see* 1-Propanol, 3,3'-iminodi-, dimethanesulfonate (ester), *p*-toluenesulfonate

# **Methotrexate (NSC-740)**

alone and in combination with daunorubicin in the remission-maintenance treatment of acute lymphocytic leukemia, 395  
 analysis of the effects of, on cell cycle kinetics, 847  
 assay for citrovorum factor in the presence of, 935  
 combined with bleomycin and vincristine plus radiation therapy in the treatment of non-oat-cell bronchogenic cancer, 377  
 combined with cytosine arabinoside and cyclophosphamide in the treatment of advanced breast and lung cancer, 1091  
 combined with 5-FU and prednisolone in the treatment of hepatoma, 1167  
 development of a microbiologic assay capable of detecting cytosine arabinoside in body fluids in the presence of, 515  
 kinetic model for the disposition and metabolism of moderate and high-dose, in man, 811  
 treatment of MAC-13 and MAC-15, adenocarcinomas of the colon in mice, 1083

# **Methyl-CCNU (NSC-95441)**

alone or combined with cyclophosphamide in the treatment of advanced gastrointestinal cancer, 1161  
 combined with cyclophosphamide in a comparative study with DTIC plus vincristine in patients with disseminated malignant melanoma, 451  
 combined with cyclophosphamide and vincristine in the treatment of small cell carcinoma of the lung in a 3-week schedule, 1127  
 compared to BCNU and CCNU with regard to sensitivity of colony-forming cells of hemopoietic tissue, Lewis lung carcinoma, and B16 melanoma, 929  
 phase II study, in the treatment of various carcinomas, sarcomas, and lymphomas, 1021  
 treatment of MAC-13 and MAC-15, adenocarcinomas of the colon in mice, 1083

**3-Methylcholanthrene (NSC-21970)**, neoplastic effect of, on human prostate in organ culture, 67

**Methyl-GAG (NSC-32946)**, combined with 5-azacytidine in previously treated adults with acute nonlymphocytic leukemia, 1043

**1-Methyl-1-nitrosourea (NSC-23909)**, a discussion of the apprehensions concerning experimental and clinical use of, 888

**Mitoclomine (NSC-114575)**, phase I-II trials in chronic lymphocytic leukemia, 1173

# **Mitomycin C (NSC-26980)**

compared to 5-FU using hepatic arterial infusion for liver metastases from colon cancer, 401  
 treatment of MAC-13 and MAC-15, adenocarcinomas of the colon in mice, 1083

**Moloney sarcoma virus-induced rhabdomyosarcoma** *see* Tumor systems, mice

# **Myeloma, multiple**

alkylator-resistant, adriamycin in the treatment of, 345  
 resistant to melphalan, treated with cyclophosphamide and prednisone with or without chloroquine, 557

# **N**

**Nakahara-Fukuoka sarcoma** *see* Tumor systems, mice

**Neuroblastoma** (*see also* Tumor systems, mice)

in children, advanced stage IV, adriamycin combined with DTIC in the treatment of, 1015  
 in children, BIC in the treatment of, 371  
 in children, DTIC in the treatment of, 351

**Nitrosoureas** *see* Individual drugs

**NSC-740** *see* Methotrexate

**NSC-752** *see* 6-Thioguanine

**NSC-755** *see* 6-Mercaptopurine

**NSC-757** *see* Colchicine

**NSC-1895** *see* Guanazole

**NSC-3053** *see* Actinomycin D

**NSC-3070** *see* Diethylstilbestrol

**NSC-3088** *see* Chlorambucil

**NSC-3590** *see* Citrovorum factor

**NSC-8415** *see* Butyric acid

**NSC-8806** *see* Melphalan

**NSC-9895** *see* Estradiol

**NSC-9900** *see* Prednisolone

**NSC-10023** *see* Prednisone

**NSC-13875** *see* Hexamethylmelamine

**NSC-15197** *see* Thallium chloride

**NSC-15200** *see* Gallium nitrate

**NSC-15780** *see* Amygdalin MF

**NSC-19893** *see* 5-Fluorouracil

**NSC-21970** *see* 3-Methylcholanthrene

**NSC-23909** *see* 1-Methyl-1-nitrosourea

**NSC-24818** *see* Podophyllotoxin

**NSC-25485** *see* Strophanthin G

**NSC-26271** *see* Cyclophosphamide

**NSC-26980** *see* Mitomycin C

**NSC-32065** *see* Hydroxyurea

**NSC-32946** *see* Methyl-GAG

**NSC-33669** *see* Emetine

**NSC-35443** *see* Papaverine

**NSC-45388** *see* DTIC

NSC-49842 see Vinblastine  
 NSC-58514 see Chromomycin A<sub>3</sub>  
 NSC-62164 see Bretium tosylate  
 NSC-63878 see Cytosine arabinoside  
 NSC-67574 see Vincristine  
 NSC-68075 see Thalicarpine  
 NSC-68626 see 1-Acetyl-2-picolinoylhydrazine  
 NSC-77213 see Procarbazine  
 NSC-79037 see CCNU  
 NSC-81430 see Cyproterone acetate  
 NSC-82151 see Daunorubicin  
 NSC-82196 see BIC  
 NSC-85998 see Streptozotocin  
 NSC-88536 see Calusterone  
 NSC-89199 see Estramustine phosphate  
 NSC-95441 see Methyl-CCNU  
 NSC-102063 see Tetramisole  
 NSC-102816 see 5-Azacytidine  
 NSC-104800 see Dibromodulcitol  
 NSC-104801 see Cytembena  
 NSC-109724 see Isophosphamide  
 NSC-112907 see Tetrahydrodouridine  
 NSC-114575 see Mitoclomine  
 NSC-118714 see L-lyxo-Hexopyranoside, 3- $\beta$ -acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1 $\alpha$ -naphthaceny-3-acetamido-2,3,6-trideoxy-,  $\alpha$ -, compd. with isopropyl alcohol (1:1)  
 NSC-118994 see Inosine dialdehyde  
 NSC-119875 see Cis-dichlorodiammineplatinum(II)  
 NSC-122819 see VM-26  
 NSC-123127 see Adriamycin  
 NSC-125066 see Bleomycin  
 NSC-128056 see  $\beta$ -Glucosidase  
 NSC-129943 see ICRF-159  
 NSC-132313 see Dianhydrogalactitol  
 NSC-139105 see Triazinate  
 NSC-140117 see 1-Propanol, 3,3'-iminodi-, dimethanesulfonate (ester), *p*-toluenesulfonate  
 NSC-141540 see VP-16-213  
 NSC-143017 see Aluminum nitrate  
 NSC-143114 see Daunomycin-semicarbazone  
 NSC-143496 see Daunomycin, *N*-(butylcarbamoyl)-  
 NSC-143504 see Concanavalin A  
 NSC-145118 see Lankacidin C  
 NSC-145668 see Cycloctidine  
 NSC-149584 see Adriamycin, 14-octanoate, hydrochloride  
 NSC-150014 see Hydrazine sulfate  
 NSC-163501 see L-[ $\alpha$ ,S,5S]- $\alpha$ -amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid  
 NSC-164011 see Rubidazole  
 NSC-166641 see Anhydro-ara-5-fluorocytidine  
 NSC-169533 see Daunorubicin-DNA  
 NSC-169534 see Adriamycin-DNA  
 NSC-169774 see 2-Bromo- $\alpha$ -ergocryptine  
 NSC-177023 see Levamisole  
 NSC-187208 see Chloroquine  
 NSC-233898 see 6-Hydroxydopamine  
 NSC-403169 see Acronycine  
 NSC-409962 see BCNU  
 Nucleosides, as potential biologic markers in Burkitt's lymphoma, 721

## O

Ototoxicity see Toxic reactions: animals  
 Ovarian cancer see Cancer, ovarian

## P

Pancreatic cancer see Cancer, pancreas

PAP (prostatic acid phosphatase)

activity of cultured cells, 59, 147  
 design of spindle poisons activated specifically by, and new methods for cytochemistry, 233

Papaverine (NSC-35443), unorthodox therapy for murine neuroblastoma with, 571

### Pharmacokinetics

analysis of the effects of antitumor drugs on cell cycle kinetics, 847

considerations of resistance to anticancer drugs, 795

cytotoxic aspects of clinical drug resistance, 805

disposition of cytosine arabinoside and its metabolites: a pharmacokinetic simulation, 861

human model for isophosphamide, 877

kinetic model for the disposition and metabolism of moderate and high-dose methotrexate in man, 811

mathematical models for cancer chemotherapy: pharmacokinetic and cell kinetic considerations, 827

preliminary model for adriamycin, 819

some fundamental considerations of the applications of, to cancer chemotherapy, 777

stochastic compartmental modeling of the disposition of DTIC, 843

### Phase I studies

of adriamycin plus 5-FU in the treatment of breast cancer and other solid tumors, 1163

of 5-azacytidine using a 24-hour continuous infusion for 5 days in the treatment of various cancers, 1123

of *Corynebacterium parvum* in the treatment of various solid tumors, 1139

of cycloctidine for solid tumors and acute leukemias, 389

of emetine in the treatment of epidermoid bronchogenic cancer, 1171

of guanazole in various tumors, 1117

of inosine dialdehyde, 1007

of isophosphamide, 751

of mitoclomine in chronic lymphocytic leukemia, 1173

of thalicarpine, a plant alkaloid, 1001

### Phase II studies

1-acetyl-2-picolinoylhydrazine in children with various malignant neoplasms, 341

of adriamycin in patients with metastatic melanoma, 1181

of BIC in primary and secondary brain tumors, 327

of BIC in the treatment of childhood malignancy, 371

of chromomycin A<sub>3</sub> in advanced colorectal carcinoma, 577

of cis-dichlorodiammineplatinum(II) and cyclophosphamide in the treatment of human malignancies, 995

of cytembena in advanced colorectal carcinoma, 581

of emetine in the treatment of epidermoid bronchogenic cancer, 1171

of ICRF-159 in advanced colorectal carcinoma, 761  
 of methyl-CCNU in the treatment of various solid carcinomas, sarcomas, and lymphomas, 1021  
 of mitoclonine in chronic lymphocytic leukemia, 1173  
 of procarbazine, streptozotocin, 6-thioguanine, or CCNU in patients with metastatic cancer of the large bowel, 333

**Pimelea simplex**, antitumor activity of, 585

#### **Platinum "blues"**

antitumor activity of, in Sarcoma 180, 589  
 platinum-pyrimidine blues, and related complexes, methods of synthesis, suggested classification scheme, and initial activity in animal tumors, 287  
 platinum uracil blue, preliminary clinical studies with, 647  
 platinum uracil blue, tissue distribution, antitumor activity in animals, and synthesis of, 629

**Platinum compounds** (see also *cis*-dichlorodiammineplatinum [II] and other specific compounds)

chemistry and biologic activity of, 589  
 clinical studies of, in various malignant diseases, 647  
 coordination complexes of, as antitumor agents, 629

**P388 leukemia** see Tumor systems, mice

**Podophyllotoxin** (NSC-24818), attempts to demonstrate cytotoxic activity by specific activation by PAP, 233

#### **Polyamines**

potential biologic markers in Burkitt's lymphomas, 721  
 urinary excretion of, in patients with advanced malignancy, 1103

**Prednisolone** (NSC-9900), combined with 5-FU and methotrexate in the treatment of hepatoma, 1167

**Prednisone** (NSC-10023)

combined with cyclophosphamide and vincristine in the treatment of diffuse non-Hodgkin's lymphoma, 421  
 combined with cyclophosphamide with or without chloroquine in the treatment of multiple myeloma resistant to melphalan, 557  
 combined with daunorubicin, cytosine arabinoside, and vincristine in the treatment of advanced adult acute leukemia, 757  
 combined with daunorubicin, 6-thioguanine, cytosine arabinoside, and vincristine in the treatment of adults with acute nonlymphocytic leukemia, 1131  
 combined with vinblastine in the treatment of acute monocytic leukemia in children, 385

**Procarbazine** (NSC-77213)

combined with actinomycin D and vinblastine in the treatment of malignant melanoma, 767  
 phase II trials with, in patients with metastatic cancer of the large bowel, 333  
 used in potential test systems in animals to determine activity against prostatic carcinoma, 175

**1-Propanol, 3,3'-iminodi-, dimethanesulfonate (ester), p-toluenesulfonate** (NSC-140117), a new methanesulfonic acid ester of aminoglycol, in the management of lung cancer, 367

**Prostatic acid phosphatase** see PAP

**Prostatic cancer** see Cancer, prostate (see also pp 1-255, National Prostatic Cancer Project Workshop)

**Pyrimidine catabolic end-products**, as potential biologic markers in Burkitt's lymphoma, 721

## **R**

#### **Radiation therapy**

combined with bleomycin, vincristine, and methotrexate in the treatment of non-oat-cell bronchogenic carcinoma, 377

combined with vincristine, cyclophosphamide, and actinomycin D in the treatment of childhood rhabdomyosarcoma, 359

extended-field, in prostatic carcinoma, 165

myocardial infarction as a possible complication of treatment with VP-16-213, mediastinal irradiation, or both, 887

for prostatic cancer in man, 251

**Rauscher leukemia** see Tumor systems, mice, MCDV-12 leukemia

#### **Rhabdomyosarcoma**

in children, 1-acetyl-2-picolinoylhydrazine in the treatment of, 341

in children, DTIC in the treatment of, 351

in children, vincristine, actinomycin D, and cyclophosphamide with or without radiation therapy in the treatment of, 359

#### **Rhodium(II) acetate**

inhibition of deamination of cytosine arabinoside by, 661  
 interaction of, with molecules of biologic importance, 611

**Rhodium(II) butyrate**, interaction of, with molecules of biologic importance, 611

**Rhodium(II) propionate**, interaction of, with molecules of biologic importance, 611

**Ridgway osteogenic sarcoma** see Tumor systems, mice

**Rubidazole** (NSC-164011)

development of resistance to, in Ehrlich ascites tumor in vivo, 301

toxicologic screening in rats, 707

## **S**

#### **Sarcoma**

advanced, adriamycin alternating with vincristine plus actinomycin D in the treatment of, 1035

*cis*-dichlorodiammineplatinum(II) plus cyclophosphamide in the treatment of, 995

osteogenic, hyperthermia as an adjuvant in the treatment of, 257

**Sarcoma 180** see Tumor systems, mice

**Southwest Oncology Group** see Cooperative groups

**Spindle poisons**, activated specifically by PAP, as potential cytotoxic agents, 233

**Squamous cell cancer** see Cancer, squamous cell

**SR61 leukemia** see Tumor systems, mice

**Stomach cancer** see Cancer, stomach

**Streptozotocin** (NSC-85998)

fate of, in the treatment of patients with advanced cancer, 547

metastatic renal adenocarcinoma produced by, 891

new model for studying the effect of, in the growth of the prostate gland in rats, 185

phase II trials with, in patients with metastatic cancer of the large bowel, 333

in the treatment of lymphoreticular malignancies, 443

used in potential test systems in animals to determine activity against prostatic carcinoma, 175

**Strophanthin G (NSC-25485)**, lack of effect on cardiac uptake of adriamycin, 765

**Structure-activity studies**  
 antitumor and immunosuppressive activities of lankacidin-group antibiotics, 919  
 the role of, in the design of antitumor agents, 679

**SV40-transformed prostatic tissue** *see* Tumor systems, hamsters

**Symposia**, proceedings of  
 National Prostatic Cancer Workshop, 1  
 Pharmacokinetic Modeling of Anticancer Drugs, 775  
 Role of Metal Complexes and Metal Salts in Cancer Chemotherapy, 589

## T

**Testicular cancer** *see* Cancer, testicular

**Tetrahydrouridine (NSC-112907)**  
 inhibition of deamination of cytosine arabinoside by, 717  
 used to enhance the oral activity of 5-azacytidine in L1210 leukemic mice, 459

**Tetramisole (NSC-102063)**, effects of, in experimental tumor systems, 697

**Thalidomide (NSC-68075)**, phase I study of, 1001

**Thallium chloride (NSC-15197)**, toxicity and antitumor activity in experimental rodent tumors, 599

**6-Thioguanine (NSC-752)**  
 combined with daunorubicin, cytosine arabinoside, prednisone, and vincristine, in the treatment of adults with acute nonlymphocytic leukemia, 1131  
 development of a microbiologic assay capable of detecting cytosine arabinoside in body fluids in the presence of, 515  
 phase II trials with, in patients with metastatic cancer of the large bowel, 333

**Toxic reactions: observations in animals**  
 cardiotoxicity of anthracycline antibiotics in rats, 707  
 evaluation of sialogic action of cyclophosphamide and anhydro-ara-5-fluorocytidine, 1019  
 hearing loss in rhesus monkeys treated with *cis*-dichlorodiammineplatinum(II), 467  
 inability of strophanthin G to affect cardiac uptake of adriamycin, 765  
 nephrotoxic effects of cytembena in dogs and monkeys, 1071

**Toxic reactions: observations in man**  
 cardiotoxicity  
 of daunorubicin and adriamycin, another hypothesis of, 258  
 of 5-FU in man, 1051  
 contact dermatitis associated with adriamycin and daunorubicin, 677  
 immediate cerebral symptoms during rapid intravenous administration of cyclophosphamide, 441  
 myocardial infarction as a possible complication of treatment with VP-16-213, mediastinal irradiation, or both, 887  
 reversible penile calcifications associated with bleomycin-induced pulmonary toxicity, 1039

**Triazinate (NSC-139105)**, an antifolate drug, preclinical studies with, in beagle dogs and rhesus monkeys, 523

**Tumor cell kill**, estimation of, from Gompertz growth curves, 267

**Tumor systems in animals**  
 hamsters, SV40-transformed prostatic tumors in, establishment of tissue cultures from, 51  
 mice  
 ADJ/PC6A tumor, antitumor activity of platinum-pyrimidine blues and related complexes against, 287  
 AKR lymphoma, activity of concanavalin A on, 319  
 B16 melanoma  
 antitumor activity of amygdalin MF as a single agent and combined with  $\beta$ -glucosidase, 939  
 differential sensitivity of colony-forming cells of, to BCNU, CCNU, and methyl-CCNU, 929  
 effects of levamisole and tetramisole in, 697  
 brain tumors, review of selected experimental models used in chemotherapy experiments, 729  
 6C3HED/OG lymphosarcoma, antitumor and immunosuppressive activities of lankacidin-group antibiotics on, 919  
 Ehrlich carcinoma  
 antitumor activity of platinum-pyrimidine blues and related complexes against, 287  
 antitumor activity of selected amino acid derivatives against, 309  
 development of resistance to rubidazole in, 301  
 interaction of rhodium(II) carboxylates with molecules of biologic importance, 611  
 Glioma 26, relationship of lipophilicity of imidazole carboxamides to activity against, 327  
 human prostatic tumors in, 47  
 KHT fibrosarcoma, activity of concanavalin A on, 319  
 LAF-17 (radiation induced) lymphoma, inhibition of antilymphoma allograft response in, by cyclophosphamide and isophosphamide, 967  
 Lewis lung carcinoma  
 antitumor activity of amygdalin MF alone and combined with  $\beta$ -glucosidase, 951  
 differential sensitivity of colony-forming cells of, to BCNU, CCNU, and methyl-CCNU, 929  
 effects of levamisole and tetramisole in, 697  
 L1210 leukemia  
 antitumor activity of amygdalin MF as a single agent and combined with  $\beta$ -glucosidase, 939  
 antitumor activity of platinum-pyrimidine blues and related complexes against, 287  
 antitumor activity of selected amino acid derivatives against, 309  
 antitumor and immunosuppressive activities of lankacidin-group antibiotics against, 919  
*cis*-dichlorodiammineplatinum(II) alone or combined with various other agents in the treatment of, 629  
 effects of levamisole and tetramisole in, 697  
 enhancement by tetrahydrouridine of the oral activity of 5-azacytidine in, 459  
 enhancement of the effectiveness of daunorubicin or adriamycin against, with ICRF-159, 689  
 preliminary observations on temperature-enhanced drug uptake by leukemic leukocytes, *in vitro*, 985



solid lymphocytic, comparative distribution studies with cycloctidine and cytosine arabinoside in, 501

L5MF-22 (radiation-induced) lymphoma, inhibition of antilymphoma allograft response in, by cyclophosphamide and isophosphamide, 967

MAC-13 and MAC-15 adenocarcinoma, chemotherapy of, with various agents, 1083

Madison 109 lung tumor, effects of levamisole and tetramisole in, 697

MCAM-7 (3-methylcholanthrene-induced) fibrosarcoma, specificity of cell membrane antigens in, 127

MCDV-12 leukemia (Rauscher), antitumor activity of platinum-pyrimidine blues and related complexes against, 287

Moloney sarcoma virus-induced rhabdomyosarcoma, effects of levamisole and tetramisole in, 697

Nakahara-Fukuoka sarcoma, antitumor activity of selected amino acid derivatives against, 309

neuroblastoma

C1300, further evaluation of, with various antitumor agents, 975

unorthodox therapy for, with 6-hydroxydopamine, bretylium tosylate, papaverine, and butyric acid, 571

P388 leukemia

antitumor activity of amygdalin MF alone and combined with  $\beta$ -glucosidase, 951

antitumor activity of amygdalin MF as a single agent and combined with  $\beta$ -glucosidase, 939

antitumor activity of *Pimelea simplex* against, 585

effects of levamisole and tetramisole in, 697

Ridgway osteogenic sarcoma, antitumor activity of amygdalin MF alone and in combination with  $\beta$ -glucosidase, 951

Sarcoma 180

antitumor activity of platinum blue complexes against, 589

antitumor activity of platinum-pyrimidine blues and related complexes against, 287

antitumor activity of selected amino acid derivatives against, 309

SR61 leukemia, antitumor activity of selected amino acid derivatives against, 309

rats

AH13, AH60C, and AH7974 hepatomas, antitumor activity of selected amino acid derivatives against, 309

brain tumors, review of selected experimental models used in chemotherapy experiments, 729

Walker 256 carcinosarcoma

antitumor activity of amygdalin MF as a single agent and combined with  $\beta$ -glucosidase, 939

antitumor activity of gallium nitrate and other group IIIa metal salts in, 599

Yoshida sarcoma, antitumor activity of selected amino acid derivatives against, 309

## V

Veterans' Administration Cooperative Urological Research Group see Cooperative groups

## Vinblastine (NSC-49842)

combined with continuous iv bleomycin in stage III testicular neoplasia, 563

combined with procarbazine and actinomycin D in the treatment of malignant melanoma, 767

evaluation in the C1300 murine neuroblastoma model, 975

with or without prednisone in the treatment of acute monocytic leukemia in children, 385

## Vincristine (NSC-67574)

combined with actinomycin D and alternating with adriamycin in the treatment of advanced sarcomas, 1035

combined with actinomycin D and cyclophosphamide with or without radiation therapy in the treatment of childhood rhabdomyosarcoma, 359

combined with bleomycin and methotrexate plus radiation therapy in the treatment of non-oat-cell bronchogenic carcinoma, 377

combined with cyclophosphamide and methyl-CCNU in the treatment of small cell carcinoma of the lung in a 3-week schedule, 1127

combined with cyclophosphamide and prednisone in the treatment of diffuse non-Hodgkin's lymphoma, 421

combined with daunorubicin, cytosine arabinoside, and prednisone in the treatment of advanced adult acute leukemia, 757

combined with daunorubicin, 6-thioguanine, cytosine arabinoside, and prednisone in the treatment of adults with acute nonlymphocytic leukemia, 1131

combined with DTIC in a comparative study with cyclophosphamide plus methyl-CCNU in patients with disseminated malignant melanoma, 451

combined with 5-FU with or without cyclophosphamide in the treatment of various adenocarcinomas, 425

combined with hydroxyurea in the treatment of metastatic renal cancer, 1159

evaluation in the C1300 murine neuroblastoma model, 975

new model for studying the effect of, on the growth of the prostate gland in rats, 185

treatment of MAC-13 and MAC-15 adenocarcinomas of the colon in mice, 1083

used in potential test systems in animals to determine activity against prostatic carcinoma, 175

Viruses, role in prostatic cancer, 17, 33, 39

VM-26 (NSC-122819), compared to VP-16-213 in childhood cancer: preliminary observations, 743

VP-16-213 (NSC-141540)

clinical antitumor and toxicity study in solid tumors, 737

compared to VM-26 in childhood cancer: preliminary observations, 743

given orally to patients with advanced neoplastic disease, 1027

myocardial infarction as a possible complication of treatment with, or mediastinal irradiation, or both, 887

## W

Walker 256 carcinosarcoma see Tumor systems, rats

Western Cancer Study Group see Cooperative groups

## Y

Yoshida sarcoma see Tumor systems, rats



## Author Index

### A

Aboul-Enein M, 367  
Adamson RH, 599  
Adolphe AB, 547  
Ahluwalia BS, 3  
Ahmann DL, 451, 1103  
Alberts DS, 345  
Albo V, 351, 989, 1097  
Allan BD, 257  
Allen LM, 811, 877  
Arena E, 765  
Aroesty J, 861  
Arya SK, 39  
Attah EB, 3  
Avery T, 743

### B

Babcock MS, 59  
Bachur NR, 677, 765  
Bagshaw MA, 165  
Baker LH, 1123  
Ball CR, 1083  
Band PR, 1139  
Barkley HT, Jr, 377  
Barlow JJ, 1157  
Barnard EA, 97  
Barzi A, 967  
Bateman JR, 1031, 1177  
Batz K, 429  
Bear JL, 611, 661  
Bellet RE, 1181  
Bender RA, 795, 805  
Bennett JM, 333  
Bergsagel DE, 537  
Berman M, 811  
Bernstein I, 1015  
Bertino JR, 523, 575, 1091  
Bhargava A, 97  
Bischoff KB, 777  
Bisel HF, 451  
Blackard CE, 225  
Blackett NM, 929  
Bleyer WA, 721, 795  
Block JB, 985  
Bluming AZ, 901  
Boldrey E, 327  
Bonadonna G, 1161  
Bonar RA, 51  
Bonmassar E, 967  
Bonnet JD, 425  
Bono VH, 481  
Bowen JM, 17  
Brandle E, 707  
Brannen GE, 127

Brema F, 890  
Brenkus LB, 847  
Broder LE, 1001, 1171  
Bruce WR, 319  
Bruckner HW, 575  
Brugarolas A, 1025  
Brunner KW, 429  
Buckner CD, 1131  
Bull MI, 1171  
Burns CP, 757

### C

Cain BF, 679  
Canellos GP, 599, 893  
Cangir A, 371  
Caoili EM, 1117  
Carter WA, 39  
Chainuvati T, 1167  
Chalbard RA, 433  
Chang H-Y, 769  
Chang IM, 611  
Chao DL, 661  
Chawla PL, 389  
Cheever MA, 1131  
Chirigos MA, 531  
Choe B-K, 147  
Chu TM, 97, 195  
Chuang S-N, 827  
Chung WS, 1157  
Coffey DS, 127, 185  
Cohen MH, 243, 751, 1001, 1171  
Cohen SS, 259  
Coleman D, 1131  
Coleman GL, 523, 1071  
Colsky J, 333  
Colvin M, 411  
Connolly CA, 3  
Cooney DA, 481  
Copeland EM III, 437  
Coune A, 209  
Courtenay VD, 929  
Cowan DH, 537  
Crafts D, 327  
Creaven PJ, 751, 811, 877, 1001, 1171  
Cunningham TJ, 1127  
Curtis JE, 537  
Cysyk RL, 685, 689

### D

Davidson JP, 287  
DeConti RC, 1091  
Dedrick RL, 795, 805  
de Duve C, 260

DeMarsh Q, 1131  
 Desmond W, 47  
 DeVita VT, 1039  
 DeWys WD, 215  
 DiDomenico E, 447  
 Dion RL, 481  
 Dittman W, 1131  
 Dmochowski L, 17  
 Dobrow RB, 1131  
 Dombrowsky P, 1027  
 Donavan MA, 1127  
 Double JA, 1083  
 Douglass HO, Jr, 1035  
 Drewinko B, 621, 665  
 Dudrick SJ, 437  
 Dymant PG, 359, 371

## E

Eagan RT, 203, 451  
 Edmonson JH, 451  
 Einhorn L, 769  
 Einstein AB, Jr, 1131  
 El-Asfour S, 843  
 El-Merzabani MM, 367  
 El-Morsi B, 367  
 Emanuel NM, 888  
 Engeler J, 767  
 Enot J, 327  
 Ertel I, 351  
 Espinoza JV, 457  
 Evans A, 1015  
 Ezdinli E, 333

## F

Faber PJ, 287  
 Fefer A, 1131  
 Fernbach DJ, 395  
 Finklestein JZ, 351, 571, 975, 1015  
 Finn C, 279  
 Firat D, 1021  
 Fischer RG, Jr, 287  
 Fleischman RW, 467  
 Fliegelman MJ, 531  
 Fortuny IE, 401  
 Fossieck BE, Jr, 1171  
 Francis RS, 1039  
 Frei E III, 389  
 Freireich EJ, 769  
 Friedman AE, 233  
 Froufe A, 1025  
 Frytak S, 405  
 Fukushima K, 309  
 Furlow WL, 203  
 Furner RL, 717

## G

Gaeta JF, 195  
 Gad-el-Mawla N, 367  
 Galbraith WM, 1019, 1061  
 Gang M, 689

Gangji D, 1173  
 Gaston MR, 697  
 Gehrke CW, 721, 1103  
 Geiser CF, 385  
 George SL, 395, 437  
 Geran RI, 729  
 Gibbons RP, 195  
 Glasofer ED, 547  
 Glidewell O, 557  
 Glucksberg H, 1131  
 Goldin A, 697, 967  
 Gomolka DM, 127  
 Gonzalez-Palacios F, 1025  
 Gordon BS, 891  
 Gormley PE, 1039  
 Gottlieb JA, 621, 665, 769  
 Gralla EJ, 523, 1071  
 Gray HB, Jr, 611  
 Grayhack JT, 139  
 Gross JF, 819

## H

Hadd HE, 119  
 Hahn RG, 405, 451, 577, 581, 761  
 Hall LM, 629  
 Hammond D, 351, 989, 1097  
 Han T, 157  
 Hañka LJ, 459  
 Hanley JA, 333  
 Hansch C, 327  
 Hansen HH, 751, 1027  
 Harada S, 919  
 Haraphongse M, 1139  
 Harris PA, 819, 985  
 Hasselback R, 537  
 Haut A, 1163  
 Henry MC, 447  
 Hensleigh D, 421  
 Herson J, 3  
 Heshmat MY, 3  
 Hesselund M, 1027  
 Heston WDW, 185  
 Hill AS, 1131  
 Hill JM, 629, 647  
 Hill NO, 647  
 Hitannant S, 1167  
 Hittle R, 1015  
 Holland JF, 557  
 Holoye PY, 377, 433, 563, 1159  
 Hoogstraten B, 1163  
 Horoszewicz JS, 39, 89  
 Horton J, 333, 1127  
 Houchens DP, 697, 967  
 Howard HTC, 585  
 Howard R, 611  
 Howden MEH, 585  
 Howe KE, 629  
 Hueser JN, 1103  
 Huff J, 1131  
 Hum GJ, 1177



Humphrey GB, 359, 395  
Hutchison DJ, 515, 935  
Hutchison GB, 57

## I

Ihde DC, 1039  
Iorio A, 967

## J

Jackson AG, 3  
Jackson MA, 3  
Jackson RA, 887  
Jacobs SA, 721  
Jaffe N, 389  
Jao-King C, 1139  
Jayaram HN, 481  
Johnson DE, 17, 195, 433, 563, 1159  
Johnson RK, 697  
Johnston CL, Jr, 105  
Joiner J, 195  
Jonas AM, 523, 1071  
Jones GW, 3  
Jones SE, 887  
Jönsson G, 229  
Jungi WF, 737  
Jurkowitz L, 333

## K

Kabra P, 327  
Kaighn ME, 59  
Kane RC, 1171  
Kapadia A, 843  
Kapoor SK, 3  
Karakousis C, 1035  
Karon M, 989  
Kashgarian M, 1071  
Kaufman J, 1007  
Kelly F, 47  
Kenis Y, 1173  
Kennedy J, 3  
Kennedy BJ, 401  
Khaliq A, 769  
Khan A, 647  
Kimball AP, 611, 661  
King JJ, 647  
Kirdani RY, 175  
Kishi T, 919  
Kjobech C, 1131  
Klein E, 157  
Klemperer M, 1015  
Kline I, 689  
Kolarić K, 1051  
Komp D, 341, 371, 395  
Koontz WW, Jr, 105  
Korman NP, 888  
Kostinas J, 767  
Kovi J, 3  
Krakoff IH, 1151  
Kuentsel SL, 459  
Kuo KC, 721, 1103

Kurnick JE, 1147  
Kyle RA, 557

## L

Lacave AJ, 1025  
Lakings DB, 721, 1403  
Land VJ, 371  
Lane DM, 359  
Lane M, 425, 1163  
Lanzotti VJ, 437  
Laster WR, Jr, 951  
Lee SH, 661  
Lehane DE, 1163  
Leikin S, 1015  
Leme PR, 811  
Levi JA, 1043  
Levin VA, 327  
Lieberman DZ, 629  
Lin H, 319, 895  
Lincoln TL, 861  
Liss RH, 501  
Lloyd HH, 267  
Loeb E, 647  
Lokey JL, 767  
Lokich JJ, 389  
Lomen PL, 1123  
Longeval E, 1173  
Loo TL, 775, 843  
Lucas AO, 3  
Lutz RJ, 795  
Lynn D, 233

## M

MacLellan A, 647  
Magrath IT, 1155  
Mahmoud ME, 367  
Malinin TI, 91  
Manak RC, 459  
Manaster J, 537  
Mansy S, 287  
Manthei RW, 547  
Marciniak TA, 577, 581, 761  
Maruyama K, 17  
Mastrangelo MJ, 1181  
Matsumoto T, 919  
Mayer SM, 929  
Meares EM, Jr, 165  
Mehta BM, 515, 935  
Mellett LB, 717, 1061  
Merchant D, 65  
Merker PC, 729  
Merriam P, 467  
Merrin C, 97, 157  
Meshnik R, 571, 975  
Meyers MB, 515  
Mittelman A, 219, 333, 751, 1007  
Mitus JW, 385  
Moertel CG, 405, 577, 581, 761, 1103  
Moncure CW, 105  
Morrison PF, 861  
Mostofi FK, 111

Movassaghi N, 989, 1097  
Moxley TE, 459  
Muggia F, 751  
Mullins GM, 411  
Munchausen LL, 643  
Murphy GP, 1, 97, 157, 175, 195, 219  
Myers RP, 203

## Mc

McInnis B, 843

## N

Neely M, 327  
Neil GL, 459, 481, 501, 1123  
Neiman PE, 1131  
Newman AD, 629  
Newton WA, 17  
Nilprabhassorn P, 1167  
Nilsson T, 229  
Nissen NI, 1027  
Nitschke R, 371  
Nkposong EO, 3  
Nkrumah FK, 1155  
Norman RL, 257  
Noyes WF, 67

## O

Ochoa M, Jr, 1151  
O'Connell MJ, 443  
Odujinrin OO, 1091  
Ohtsuki Y, 17  
Olisa E, 3  
Olweny CLM, 721  
Ootsu K, 919  
Osbaldiston GW, 523, 1071  
Osman A, 367  
Ostrovskaya LA, 888  
Ostrowski W, 97

## P

Palyi I, 493  
Paul BD, 233  
Paulson DF, 51  
Peale A, 985  
Pedersen H, 1027  
Peresie HJ, 287  
Perkins IV, 1155  
Perlia CP, 995  
Perlin E, 767  
Piel LJ, 995  
Pinkerton D, 341  
Piver MS, 1157  
Plapinger RE, 233  
Pontes JE, 147  
Popović S, 1051  
Porcile G, 890  
Pratt C, 743  
Pretlow TG II, 143  
Prout GR, 195  
Pugh RP, 1031  
Pullen DJ, 359

## R

Ragab AH, 359  
Rahn RO, 643  
Rainen L, 611  
Rakieten N, 891  
Rapp F, 33  
Ray GR, 165  
Razek AA, 395  
Reed A, 989, 1097  
Reich C, 51  
Reich SD, 677  
Reid JW, 767  
Reitemeier RJ, 405, 577, 581, 761  
Reiter W, 765  
Ridgway H, 629  
Riva A, 1161  
Rivas A, 1025  
Rivera G, 743  
Robinson WA, 1147  
Rodriguez A, 457  
Rodriguez L, 1159  
Roesler AR, 447  
Rohner TJ, 33  
Rose NR, 147  
Rosenberg B, 287, 589  
Rosenberg PJ, 377  
Rossi A, 1161  
Rosso R, 890  
Roth A, 1051  
Rudders RA, 421  
Ryan JA, 481  
Ryssel HJ, 429

## S

Sadee W, 279  
Sakurai Y, 367  
Salem P, 1117  
Salmon SE, 345  
Salzman JR, 165  
Samson MK, 1123  
Samuels ML, 377, 433, 437, 563, 1159  
Sandberg AA, 175  
Sanford EJ, 33  
Saroff J, 195  
Sato G, 47  
Sawarnkatata P, 1052  
Sawicki WL, 523  
Schabel FM, Jr, 261, 951  
Schaeppi U, 467  
Schechter JP, 887  
Schimpff SC, 1055  
Schmidt JD, 195  
Schneyer CA, 1019  
Schutt AJ, 405, 577, 581, 761  
Scott WW, 195  
Selawry OS, 751, 1001  
Seligman AM, 233  
Seligman BR, 557  
Seman G, 17  
Senn HJ, 737  
Serio G, 611

Shah KV, 51  
 Shannon WA, Jr, 233  
 Sharief Y, 51  
 Shukla SK, 219  
 Sieber SM, 599, 915  
 Sieper WJ, 1181  
 Silver RT, 557  
 Simon R, 1155  
 Sitarz AL, 989, 1097  
 Skovsgaard T, 301  
 Sloan WR, 185  
 Smith F, 1117  
 Smith MJV, 105  
 Smith P, 209  
 Smith TL, 377  
 Sonntag RW, 429  
 Speer RJ, 629  
 Sponzo RW, 1127  
 Stadnicki SW, 467  
 Stambaugh JE, 547  
 Stephens RL, 1163  
 Sternberger NJ, 233  
 Stewart DP, 629  
 Stolinsky DC, 1031  
 Strøyer I, 1027  
 Stryckmans P, 1173  
 Stuckey WJ, 395  
 Sutow WW, 341  
 Swiniarski JK, 939

## T

Talley RW, 425, 1117  
 Tashima CK, 441  
 Taylor SG III, 333  
 Taylor SG IV, 1127  
 Tejada F, 243, 751, 1001  
 Tekuzman G, 1021  
 Theologides A, 401  
 Thomas ED, 1131  
 Tittle K, 571, 975  
 Tormey DC, 1103  
 Toyoshima S, 309  
 Trantum BL, 1163  
 Troetel WM, 547  
 Trouet A, 260  
 Tucker WG, 425

## U

Umsawasdi T, 1052, 1167

Urtasun RC, 1139  
 Utz DC, 203

## V

Vaitkevicius VK, 1117  
 Valeriote F, 895  
 VanCamp L, 287  
 Varkarakis MJ, 97, 175  
 Venditti JM, 689  
 Vergara JR, 51  
 Vietti TJ, 341  
 Viranuvatti V, 1167

## W

Waalke TP, 721, 1103  
 Wajzman Z, 157  
 Walcroft MJ, 319  
 Wallace HJ, Jr, 557  
 Ware DE, 1147  
 Wasserkrug HL, 233  
 Weiner J, 571, 975, 989, 1097  
 Weiss AJ, 547  
 Welvaart K, 219  
 Wheeler DMS, 258  
 White M, 1147  
 Wiernik PH, 443, 1043  
 Wiig KM, 847  
 Williams AO, 3  
 Wilson CB, 327  
 Wittes RE, 1151  
 Wodinsky I, 729, 939  
 Woo KB, 847  
 Woodman RJ, 689  
 Woods WA, 531

## Y

Yamanaka H, 175

## Z

Zaharko DS, 795  
 Zbinden G, 707  
 Zeigel RF, 39  
 Ziegenfuss J, 547  
 Ziegler JL, 1155  
 Zumwalt RW, 721, 1103